Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530192 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Profiling Protocol (SCRI-CA-001)
A Early Phase 1 study of Refractory Cancer, sponsored by Scottsdale Healthcare.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 86
- Enrollment target
- 9
- Study locations
NCT00530192: Completed Early Phase 1 study of Refractory Cancer, sponsored by Scottsdale Healthcare.
NCT00530192 is a Early Phase 1 study of Refractory Cancer that has completed, run by Scottsdale Healthcare. The registered enrollment target is 86 participants, below the 125-participant average among 15 other Refractory Cancer trials with a reported enrollment target (31% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00530192, a Early Phase 1 study of Refractory Cancer, has completed, sponsored by Scottsdale Healthcare.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 86 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on. To be eligible, patients must have received at least two lines of prior chemotherapeutic, hormonal or biological regimens for advanced disease, have measurable or evaluable, refractory disease and have clear documentation of the time between treatment start and documented progression on the last treatment prior to study entry. Eligible patients must undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH and/or DNA microarray analysis.
Conditions Studied
Interventions
- OTHER Treatment based on Molecular Profiling
Study Locations (9)
Arizona
- TGen Clinical Research Services - Scottsdale
- Mayo Clinic - Scottsdale
California
- Tower Oncology - Beverly Hills
- Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center - Los Angeles
Texas
- South Texas Oncology Hematology - San Antonio
- Tyler Cancer Center - Tyler
Alabama
- Oncology Specialties - Huntsville
Indiana
- Central Indiana Cancer Center - Indianapolis
South Carolina
- Cancer Center of the Carolinas - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-03 |
| Phase | Early Phase 1 |
What the finished NCT00530192 record still lists
NCT00530192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 125-participant average among 15 other Refractory Cancer trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Refractory Cancer appearing as the primary indexed condition, and to 1 intervention - of which Treatment based on Molecular Profiling is the first listed.
NCT00530192 lists 9 locations in 6 states (Arizona, California, Texas).
Frequently Asked Questions
What is clinical trial NCT00530192 about?
NCT00530192 is a clinical study titled "Molecular Profiling Protocol (SCRI-CA-001)". This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has pro...
What is the current status of trial NCT00530192?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2006-09. Estimated completion is 2009-03.
What conditions does trial NCT00530192 study?
This clinical trial studies the following conditions: Refractory Cancer.
What interventions are being tested in trial NCT00530192?
The interventions under investigation include: Treatment based on Molecular Profiling (OTHER).
Who is sponsoring clinical trial NCT00530192?
This trial is sponsored by Scottsdale Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00530192 being conducted?
This trial has 9 study locations across Alabama, Arizona, California, Indiana, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00530192's enrollment target sits among peer trials
86 6th of 15 higher than 10 of 15 other Refractory Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia